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NF-jB Mediates Mitogen-Activated Protein Kinase
Pathway-Dependent iNOS Expression in Human
Melanoma
Deon G. Uffort1, Elizabeth A. Grimm1 and Julie A. Ellerhorst1
Tumor expression of inducible nitric oxide synthase (iNOS) predicts poor outcomes for melanoma patients. We
have reported the regulation of melanoma iNOS by the mitogen-activated protein kinase (MAPK) pathway. In
this study, we test the hypothesis that NF-kB mediates this regulation. Western blotting of melanoma cell lysates
confirmed the constitutive expression of iNOS. Western blot detected baseline levels of activated nuclear
extracellular signal-regulated kinase and NF-kB. Indirect immunofluorescence confirmed the presence of NF-kB
p50 and p65 in melanoma cell nuclei, with p50 being more prevalent. Electrophoretic mobility shift assay
demonstrated baseline NF-kB activity, the findings confirmed by supershift analysis. Treatment of melanoma
cells with the MEK inhibitor U0126 decreased NF-kB binding to its DNA recognition sequence, implicating the
MAPK pathway in NF-kB activation. Two specific NF-kB inhibitors suppressed iNOS expression, demonstrating
regulation of iNOS by NF-kB. Several experiments indicated the presence of p50 homodimers, which lack a
transactivation domain and rely on the transcriptional coactivator Bcl-3 to carry out this function. Bcl-3 was
detected in melanoma cells and co-immunoprecipitated with p50. These data suggest that the constitutively
activated melanoma MAPK pathway stimulates activation of NF-kB hetero- and homodimers, which, in turn,
drive iNOS expression and support melanoma tumorigenesis.
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INTRODUCTION
Malignant melanoma is currently the most virulent form of
skin cancer, with incidence and mortality rates steadily rising
in the US population (Jemal et al., 2007). Although much
improvement has been achieved regarding the treatment of
early-stage disease, many patients die each year from
melanoma metastases as tumor cells become increasingly
resistant to chemotherapy. As such, the elucidation of
pathways supporting metastatic cell growth is needed to
develop specific targeted therapies for advanced disease.
The p44/42 mitogen-activated protein kinase (MAPK)
pathway is arguably the most critical signaling cascade
supporting the uncontrolled growth of melanoma cells
(Smalley, 2003). In normal cells, the MAPK pathway is
cytokine inducible. Signal induced by ligand binding is
transported to a series of protein kinases that eventually
culminate in the phosphorylation and activation of the
extracellular signal-regulated kinase (ERK). Activated ERK
translocates to the nucleus and initiates the transcription of a
variety of growth-related genes. In melanoma cells, the
MAPK pathway is constitutively active, a condition attributed
in part to somatic mutations of NRAS and BRAF, which occur
in the majority of cases (Goydos et al., 2005). The aberrant
activation of this pathway confers a protective benefit to
melanoma cells by driving their proliferation and survival.
The critical nature of the MAPK pathway has generated
interest in melanoma-specific targets downstream of ERK that
may participate in these oncogenic processes.
One such target of particular interest to our laboratory is
inducible nitric oxide synthase (iNOS). The catalytic product of
iNOS is nitric oxide (NO), a diatomic free radical that mediates
processes such as neurotransmission, vasodilation, and host
defense in normal cells. NO has been shown to contribute to the
pathogenesis of a variety of cancers, as well. (Thomsen et al.,
1994; Cobbs et al., 1995). Specifically, in melanoma, iNOS-
generated NO has been shown to protect tumor cells from
apoptosis (Salvucci et al., 2001; Tang and Grimm, 2004). We
have recently reported that the MAPK pathway drives constitutive
iNOS expression in melanoma cells (Ellerhorst et al., 2006).
Furthermore, we have published data demonstrating an associa-
tion of tumor iNOS expression with poor prognosis in patients
diagnosed with stage III melanoma (Ekmekcioglu et al., 2006).
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The findings described above have prompted us to explore
the molecular links between melanoma ERK and iNOS, to
further clarify this tumor-promoting pathway. A particularly
promising candidate protein is the transcription factor NF-kB,
the activation of which is a hallmark of many cancers,
including melanoma. (Wang et al., 1999; Huang et al., 2000;
Dhawan and Richmond, 2002; Tian et al., 2006). NF-kB
consists of a family of structurally related proteins, including
Rel A (p65), Rel B, c-Rel, NF-kB1 (p50/p105), and NF-kB2
(p52/p100). In quiescent cells, NF-kB exists as cytoplasmic
hetero- or homodimers associated with an inhibitory protein
belonging to the IkB family. Upon appropriate cytokine
stimulation, IkB kinase (IKK) induces the phosphorylation of
IkB, promoting its subsequent ubiquitination and degradation
in the proteasome (Baldwin, 1996). This process allows the
translocation of NF-kB to the nucleus where it binds to target
DNA elements and induces transcription of various genes
involved in inflammation and survival, including iNOS
(Taylor et al., 1998). Evidence for a role of MAPK in NF-kB
activation has been reported in several nonmelanoma
systems, as well as in the HS294T human melanoma cell
line (Wang et al., 1999; Dhawan and Richmond, 2002;
Kurland et al., 2003; Jiang et al., 2004).
We have thus hypothesized that NF-kB serves as the
regulatory link between the MAPK pathway and iNOS
expression in human melanoma cells. In this study, we
explore this proposed sequence of molecular signaling events
and show that, indeed, the constitutively activated melanoma
MAPK pathway drives NF-kB activation, which, in turn
induces iNOS expression.
RESULTS
Human melanoma cells constitutively express activated ERK,
activated NF-jB, and iNOS
Initial experiments were performed to demonstrate the
presence in melanoma cells of the three proteins included
in our proposed pathway: ERK, NF-kB, and iNOS. The
human melanoma cell lines WM35, WM793, MeWo, and
HS294T, as well as primary melanocytes (FMC7C and
FMC14C), were used in these experiments. WM793 and
WM35 carry BRAF T1799A mutations, whereas MeWo,
HS294T, and both melanocyte lines are BRAF wild type
(Figure S1). None of these lines carry NRAS mutations.
Nuclear extracts prepared from these cells under basal
growth conditions contained both NF-kB p50 and p65, and
phosphorylated ERK (pERK), indicating the presence of these
proteins in the activated form (Figure 1a). Nuclear expression
varied from one cell line to the next, but tended to be higher
in the melanoma cells when compared to the melanocytes
(Figure 1c). A western blot of whole-cell lysates from the
same cells revealed the constitutive presence of iNOS protein
and demonstrated the same pattern of higher levels in the
melanoma cells (Figures 1b and c). An unanticipated
observation was the presence of iNOS protein in the nuclear
extracts of the melanoma cell lines and melanocytes
(Figure 1b), a finding that has not been previously reported.
Indirect immunofluorescence studies were next carried
out to confirm the nuclear localization of NF-kB in these
cells. In keeping with the immunoblotting data, constitutive
translocation of NF-kB p50 and p65 to the nuclei of
melanoma cells was demonstrated (Figure 2). Because
nuclear NF-kB can exist as p50/p65 heterodimers or p50
homodimers, the prevalence of each of these NF-kB subunits
was examined in the immunofluorescently stained cells.
Among the melanoma cell lines, there was a significant
difference in the number of cells expressing nuclear p50
and p65, with some cells expressing only p50 (Figure 3).
This finding was not observed in the melanocytes (FMC7C).
These data suggest that melanoma cells utilize both hetero-
and homodimeric NF-kB forms for transcriptional activa-
tion, and that the p50 homodimer activity may be tumor
specific.
The melanoma MAPK pathway regulates NF-jB
The first segment of the proposed MAPK/NF-kB/iNOS path-
way involves the regulation of melanoma NF-kB by MAPK.
An electrophoretic mobility shift assay (EMSA), carried out
with nuclear extracts from WM793 cells at baseline, revealed
NF-kB binding to its consensus oligonucleotide DNA target
sequence (Figure 4a). Supershift experiments with antibodies
to NF-kB p50 and p65 revealed even greater retardation of
the DNA/protein/antibody complexes. The antibody to NF-kB
p50 produced a more complete supershift than antibody to
the p65 subunit, consistent with the retardation of both p50
homodimers and p50/p65 heterodimers by the anti-p50
antibody, whereas the p65 antibody recognizes only the
heterodimers, leaving the homodimers unaffected (Figure 4b).
Additional EMSA experiments were performed using
WM793 cells to assess the effects of the MEK inhibitor
U0126 on NF-kB nuclear-binding activity to test the
hypothesis that NF-kB is regulated by the melanoma MAPK
pathway. These experiments revealed diminished NF-kB
binding as early as 2 minutes, with nearly complete
abrogation of activity after 5 minutes of exposure to U0126
(Figure 4c). Experiments repeated with MeWo cells yielded
similar results (data not shown). These data convincingly
support the activation of NF-kB by the MAPK pathway in
melanoma cells.
NF-jB regulates iNOS expression in melanoma cells
The second segment of the proposed pathway involves the
induction of melanoma iNOS expression by NF-kB. To
examine this regulatory event, melanoma cells were treated
with each of two inhibitors that target different aspects of NF-
kB activation. The first, NF-kB activation inhibitor, interferes
with the transcriptional ability of NF-kB, whereas the second
inhibitor, IKK-2 inhibitor V, selectively blocks IkBa phos-
phorylation, preventing the translocation of NF-kB to the
nucleus.
Figure 5a shows the inhibition of iNOS protein expression
in MeWo cells over the course of a 48-hours incubation with
NF-kB activation inhibitor. Similar findings are demonstrated
in WM793 cells treated with IKK-2 inhibitor V (Figure 5b); in
this experiment, the decline in iNOS levels is preceded by a
reduction in phosphorylation of IkBa. With both inhibitors,
the stable, dimeric iNOS functional unit persists for the first
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Figure 2. Nuclear localization of NF-jB p50 and p65. Immunofluorescent staining reveals the presence of the NF-kB subunits in (a) MeWo and (b) HS294T
cells.
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Figure 1. Expression of activated NF-jB, activated ERK, and iNOS in melanoma cell lines and melanocytes. (a) Western blotting of nuclear extracts confirms
the nuclear localization of phosphorylated extracellular signal-regulated kinase (pERK), and NF-kB p50 and p65 in these cell lines. Histone serves as a loading
control. (b) Western blot of whole-cell lysates demonstrates the constitutive presence of inducible nitric oxide synthase (iNOS) in melanoma cells and
melanocytes. iNOS is present in nuclear extracts as well. (c) Normalization of the immunoblotting results in (a and b) to the histone or actin bands is shown, to
control for differences in loading and transfer. The iNOS chart refers to cytoplasmic levels. m, BRAF mutant cell lines; w, BRAF wild-type cell lines.
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12 hours, but is markedly diminished thereafter. Similar
findings were seen with WM35 cells (data not shown). These
results are consistent with the hypothesis that NF-kB in
human melanoma induces iNOS expression.
Melanoma cells express the transcriptional coactivator Bcl-3
that complexes with NF-jB p50
Data from several of the experiments described above
indicated the presence of both NF-kB p50 homodimers and
p50/p65 heterodimers in the nuclei of melanoma cells. The
p50 homodimer binds DNA in vitro, but lacks a transcrip-
tional activation domain and, consequently, initiates tran-
scription weakly, if at all. In fact, this NF-kB homodimer
appears to function as transcriptional inhibitor in some cell
types by competing with p50/p65 for promoter binding (Kang
et al., 1992; Plaksin et al., 1993). Countering this inhibitory
effect in a variety of transformed cell types is the oncoprotein
Bcl-3, which binds NF-kB p50 homodimers and robustly
coactivates transcription (Fujita et al., 1993). Experiments
were thus conducted to explore a potential role of Bcl-3 in
melanoma NF-kB p50 transcriptional coactivation. Western
blots of whole-cell lysates and nuclear extracts from mela-
noma cells revealed the presence of the Bcl-3 protein in both
the cytoplasmic and nuclear compartments (Figure 6a).
Notably, Bcl-3 was virtually undetectable in melanocytes.
Subsequently, the association of Bcl-3 and NF-kB p50 in
melanoma cells was examined. Proteins from whole-cell
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Figure 3. Comparison of the prevalences of NF-jB p50 and p65 signals in
the nuclei of melanoma cells and melanocytes. A significantly higher number
of melanoma cells express p50 relative to p65. Error bars represent the
mean±s.d. *P-values were found to be statistically significant by w2-analysis.
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Figure 4. Melanoma NF-jB is regulated by the MAPK pathway. (a) Electrophoretic mobility shift assay (EMSA) was carried out with 32P-labeled NF-kB target
oligonucleotide and 4mg of nuclear protein from unstimulated WM793 cells. Binding experiments were performed in the presence of a specific competitor
(unlabeled NF-kB oligonucleotide), a nonspecific competitor (SP1 target oligonucleotide), and in the absence of competitor. Results demonstrate NF-kB-binding
activity in these lysates. (b) Supershift experiments were conducted to confirm the specificity of NF-kB binding. Lysates (4 mg) were incubated with 1 mg of
antibody to p50 or p65, followed by EMSA analysis. (c) Nuclear extracts of WM793 cells treated with 10 mm U0126 were prepared and examined for NF-kB
activity. Reversal of NF-kB binding is observed. Sp, specific.
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Figure 5. NF-jB regulates iNOS expression in melanoma cells. MeWo cells
(a) were treated with the NF-kB activation inhibitor (10 mM) and WM793 cells
(b) with IkB kinase (IKK)-2 inhibitor V (1 mM) over a time course of up to 48
hours. Western blotting was performed for inducible nitric oxide synthase
(iNOS) protein and, in the case of IKK-2 Inhibitor V, for total and
phosphorylated IkBa.
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lysates were immunoprecipitated with rabbit IgG or anti-
Bcl-3 antibody, followed by western blotting with antibody to
p50. Figure 6b demonstrates the presence of NF-kB p50 in
the Bcl-3 immunoprecipitates, indicating the presence of
Bcl-3/p50 complexes in melanoma cells, with the potential
for transcriptional activity.
DISCUSSION
The Ras/Raf/MEK/ERK pathway is a major signaling pathway
involved in tumor cell growth and survival. As human
melanoma is driven by constitutive activation of this path-
way, elucidation of downstream effector molecules is critical
to the understanding of melanoma pathobiology. We have
previously reported the positive regulation of melanoma
iNOS expression by the MAPK pathway and the profoundly
negative clinical implications of tumor iNOS expression in
this malignancy (Ellerhorst et al., 2006; Ekmekcioglu et al.,
2006). We now show that NF-kB mediates this regulatory
event. Previous work in the literature has described the
activation of NF-kB by the MAPK pathway in the HS294T
human melanoma cell line (Dhawan and Richmond, 2002).
Our data now confirm and extend this finding, as we
demonstrate that the inhibition of MAPK signaling with the
MEK inhibitor U0126 is accompanied by diminished nuclear
NF-kB DNA binding. Furthermore, this is this first study to
show that NF-kB regulates expression of iNOS in melanoma
cells. Notably, the MAPK/NF-kB/iNOS pathway was demon-
strated in both BRAF mutant and wild-type cells, suggesting
that the source of MAPK activation does not alter these
downstream events.
An unexpected finding was the presence of iNOS in the
nuclei of cultured melanoma cells and melanocytes.
Although nuclear iNOS has been reported in neutrophils
and adipocytes of rat origin (Giordano et al., 2002; Saini
et al., 2006), this is the first description of iNOS in the nuclei
of human cells. Of note, endothelial NOS has been detected
in the nuclei of cultured human mast cells (Gilchrist et al.,
2004). In those cell lines, endothelial NOS phosphorylation
preceded translocation from the cytoplasm to the nucleus.
The specific role of nuclear NOS and, implicitly, nuclear NO,
has yet to be explored. In melanoma cells, it could be
hypothesized that nuclear compartmentalization of iNOS and
NO may confer a strategic advantage in terms of efficient
modification of DNA and nuclear proteins by NO, in such a
way as to promote growth and survival. Although nuclear
iNOS was detected in melanocytes as well, these normally
quiescent cells are maintained in growth media containing
potent mitogens such as cholera toxin and phorbol myristate
acetate, providing growth pathway stimulation similar to that
seen in tumor cells. It therefore remains to be determined
whether nuclear translocation of iNOS is a tumor-specific
event. Future research in our laboratory will address this issue
as well as the question of iNOS phosphorylation, as has been
described for endothelial NOS.
The presence of NF-kB p50 homodimers in the nuclei of
melanoma cells is an intriguing finding. This NF-kB subtype
may be involved in the competitive transcriptional inhibition
of p50/p65, a function frequently attributed to the p50
homodimer (Kang et al., 1992; Plaksin et al., 1993).
However, the expression of the transcriptional coactivator
Bcl-3 by the melanoma cell lines, and the complexing of
Bcl-3 with p50, provides preliminary evidence to suggest that
the p50 homodimers may be transcriptionally active. The
oncoprotein Bcl-3 is a member of the IkB family of NF-kB-
binding proteins. The BCL3 gene, located on chromosome
19, is translocated intact and is activated in cases of
t(14;19)(q32.3;q13.2) B-cell chronic lymphocytic leukemia
(Ohno et al., 1990). Bcl-3 has additionally been implicated in
the pathogenesis of nasopharyngeal carcinoma, breast
cancer, and a variety of lymphomas, all cases giving evidence
for coactivation of NF-kB p50 by Bcl-3 as the transforming
event (Fujita et al., 1993; Watanabe et al., 1997; Cogswell
et al., 2000; Thornburg et al., 2003; Mathas et al., 2005).
Bcl-3 expression and its interaction with NF-kB p50 have not
been previously reported in melanoma. It is interesting to
speculate that Bcl-3/p50 complexes may be important in the
transcription of melanoma-promoting genes, such as INOS.
In summary, we have further defined the pathway leading
from the constitutively active melanoma MAPK pathway to
iNOS expression by demonstrating that NF-kB is an important
intermediary protein. In the process, we have made the
previously unreported observations of the nuclear localization
of iNOS and of Bcl-3/NF-kB p50 complexes in cultured
melanoma cells. These findings will stimulate further explora-
tion of these regulatory molecules and pathways, always with
the ultimate goal of identifying targets for future therapy.
MATERIALS AND METHODS
Cell lines
Dr Robert Kerbel (Sunnybrook Health Science Center, Toronto, ON,
Canada) provided the human melanoma cell lines WM793 and
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Figure 6. Melanoma cells express Bcl-3/p50 complexes. (a) Whole-cell
lysates and nuclear extracts from melanoma cells and melanocytes were
used to carry out western blotting for Bcl-3. (b) Whole-cell lysates from
melanoma cells were used for immunoprecipitation with anti-Bcl-3 antibody
followed by western blotting with anti-p50.
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WM35, Dr David Menter (MD Anderson Cancer Center) provided
the human metastatic melanoma MeWo cell line, and Dr Ann
Richmond (Vanderbilt University School of Medicine, Nashville,
TN) provided the HS294T melanoma cell line. BJ fibroblasts were
purchased from the ATCC (Manassas, VA). Cells were grown in
p line RPMI 1640 medium, supplemented with 10% fetal bovine
serum. Primary melanocytes FMC7C and FMC14C were derived
from neonatal foreskin and were maintained in MCDB-153 media
(Sigma, St Louis, MO), supplemented with 1% fetal bovine serum,
10 ngml1 phorbal-12-myristate-13-acetate (Calbiochem, San Die-
go, CA), 1 ngml1 basic fibroblast growth factor (Invitrogen,
Carlsbad, CA), 5mgml1 transferrin (Sigma), 10 nM cholera toxin
(Calbiochem), 0.1mM 3-isobutyl-1-methylxanthine (Calbiochem),
30 mgml1 bovine pituitary extract (Sigma), and 5mgml1 insulin
(Sigma). All cells were maintained at 37 1C with 5% CO2.
Reagents and antibodies
NF-kB activation inhibitor and IKK-2 inhibitor V were purchased
from Calbiochem and U0126 from Cell Signaling Technology
(Beverly, MA). Protein A agarose was obtained from Sigma.
Antibodies to ERK, pERK, IkBa, and phosphorylated IkBa were
purchased from Cell Signaling Technology. Antibodies to histone,
iNOS, and NF-kB p50 and p65 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). The anti Bcl-3 antibody was
purchased from Abcam (Cambridge, MA).
Whole-cell extracts and western blotting
Cells were washed with cold phosphate-buffered saline (PBS) and
harvested into PBS with 1mM phenylmethylsulfonyl fluoride. Cell
pellets were then treated with lysis buffer (140mM NaCl, 25mM Tris-
HCl (pH 7.4) and 1% NP-40) with freshly added protease inhibitor
cocktail (BD Biosciences, San Jose, CA). The supernatants were then
collected after rigorous agitation and protein concentration was
measured. SDS–PAGE separated the proteins that were transferred
to a nitrocellulose membrane and blocked for 1 hour in 5% nonfat
milk in PBS. Primary antibody was diluted in 5% nonfat dry
milk/PBS/0.1% Tween and incubated overnight at 4 1C, followed
by 45 minutes incubation with horseradish peroxidase-labeled
secondary antibody, again diluted in 5% nonfat dry milk/PBS/
0.1% Tween. Membrane development was achieved with
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Piscataway, NJ).
Nuclear extracts
The two extraction buffers used, A and B, were composed of the
following reagents: buffer A: 10mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (pH 7.9), 2mM MgCl2, 10mM KCl, 0.1mM
EDTA, 0.1mM EGTA, 5mM NaF, 1mM Na3VO4; buffer B: 20mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.4 M NaCl, 1mM
EDTA, 1mM EGTA, 5mM NaF, 1mM Na3VO4. Cells were washed
with cold PBS and harvested into PBS/1mM phenylmethylsulfonyl
fluoride. Cells were then treated with cold buffer A, followed by the
addition of protease inhibitor cocktail 1:50. After the addition of
10% NP-40 and centrifugation at 3,500 g, the cytoplasmic fraction
was collected. The remaining pellet was washed three times with
buffer A, followed by the addition of buffer B and 1:50 protease
cocktail inhibitor. After final centrifugation at 16,000 g, the nuclear
fraction was collected.
Indirect Immunofluorescence
Cells grown on chamber slides were fixed with 2% paraformalde-
hyde on ice (30 minutes), blocked with 5% serum in PBS (30 minutes
room temperature), and incubated with primary antibody diluted in
blocking solution (2 hours, 4 1C). This was followed by incubation
with fluorescein isothiocyanate-labeled secondary antibody (1 hour,
room temperature). Staining was observed and imaged with a Nikon
Eclipse TE 2000-U microscope equipped with a Nikon digital DXM
1200F camera.
Electrophoretic mobility shift assay
Nuclear protein extracts for EMSA were prepared as described
above. The NF-kB, AP2, and SP1 target oligonucleotides and gel
shift binding buffer were purchased from Promega (Madison, WI).
Binding reactions were performed with 4mg of nuclear extract and
1.75 pmol of NF-kB target oligonucleotide (unlabeled or end-labeled
with 32P). AP2 or SP1 target DNA sequences were used as
nonspecific competitor oligonucleotides. The sequence of the
double-stranded NF-kB target oligonucleotide is:
50-AGTTGAGGGGACTTTCCCAGGC-30
30-TCAACTCCCCTGAAAGGGTCCG-50
DNA–protein complexes were resolved on a 6% nondenaturing
gel. The gel was dried and exposed to film at 70 1C. For supershift
experiments, 2–4mg of nuclear extracts were incubated with
antibodies to the different subunits of NF-kB for 20 minutes prior
to the addition of the radiolabeled probe.
Immunoprecipitation
Whole-cell lysates were prepared as described above. A mixture of
protein A agarose, ice-cold PBS, and 1mg of anti-Bcl-3 or rabbit IgG was
tumble incubated overnight at 4 1C.Whole-cell extracts were precleared
with protein A agarose for 30 minutes at 4 1C followed by high-speed
centrifugation. Precleared lysates were added to the protein A
agarose–antibody mixture and incubated for 2 hours at 4 1C. Complexes
were washed with wash buffer (0.1% Triton X-100, 50mM Tris (pH 7.4),
300mM NaCl, and 5mM EDTA), resuspended in SDS–PAGE loading
buffer, and examined by western blotting.
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